drugset / Trial / NCT01303887
A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients
Phase 3
Completed
680 enrolled
University of Liverpool
Cancer Research UK · collabLiverpool University Hospitals NHS Foundation Trust · collabRoche Pharma AG · collab
RandomizedParallel-groupTreatment
Summary
The purpose of this study is to determine whether R-FC is more beneficial that R-CVP in the treatment of older patients (aged 60 or over) with Follicular Lymphoma (FL).
Timeline
- Start
- 2009-10
- Primary completion
- 2023-05-11
- Completion
- 2023-05-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 250 mg/m2 | Oral |
| Subject | Fludarabine | Small molecule | 40 mg/m2 | Oral |
| Comparator | Prednisolone | Other / unclassified | 40 mg/m2 | Oral |
| Comparator | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Comparator | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |